The American Journal of Medicine
Volume 122, Issue 10 , Pages 919-930 , October 2009

Incidence of Thrombocytopenia in Hospitalized Patients with Venous Thromboembolism

  • Paul D. Stein, MD

      Affiliations

    • Research and Advanced Studies Program, Michigan State University, College of Osteopathic Medicine, Detroit Medical Center Campus, Detroit, Mich
    • Corresponding Author InformationRequests for reprints should be addressed to Paul D. Stein, MD, 44405 Woodward Avenue, Pontiac, MI 48341-5023
    • ,
  • Russell D. Hull, MBBS, MSc

      Affiliations

    • Department of Medicine, University of Calgary, Alberta, Canada
    • ,
  • Fadi Matta, MD

      Affiliations

    • Research and Advanced Studies Program, Michigan State University, College of Osteopathic Medicine, Detroit Medical Center Campus, Detroit, Mich
    • ,
  • Abdo Y. Yaekoub, MD

      Affiliations

    • Department of Internal Medicine, St. Joseph Mercy Oakland Hospital, Pontiac, Mich
    • ,
  • Jane Liang, MSc

      Affiliations

    • Department of Medicine, University of Calgary, Alberta, Canada

  • Image Result

    Proportional effects of unfractionated heparin (UFH) and low-molecular weight heparin (LMWH) on heparin-associated thrombocytopenia in medical and surgical patients who received prophylaxis. Summary a

    Proportional effects of unfractionated heparin (UFH) and low-molecular weight heparin (LMWH) on heparin-associated thrombocytopenia in medical and surgical patients who received prophylaxis. Summary and individual study results are shown. All studies were prospective with >100 patients in each arm. Black squares = point estimates (with area proportional to number of events) and horizontal lines = 95% confidence interval (CI) for observed effects in different subgroups. Diamonds = point estimate and 95% CI for overall effects, with proportional reductions indicated alongside. Solid vertical line = hazard ratio of 1.0 (ie, no effect of treatment), and dotted vertical line = observed overall effect. DVT = deep venous thrombosis; VTE = venous thromboembolism; surg = surgical; med = medical; gyn = gynecological.

  • Image Result
    Proportional effects of unfractionated heparin (UFH) and low-molecular weight heparin (LMWH) on heparin-associated thrombocytopenia in patients who received treatment. Black squares = point estimates

    Proportional effects of unfractionated heparin (UFH) and low-molecular weight heparin (LMWH) on heparin-associated thrombocytopenia in patients who received treatment. Black squares = point estimates (with area proportional to number of events) and horizontal lines = 95% confidence interval (CI) for observed effects in different subgroups. Diamonds = point estimate and 95% CI for overall effects, with proportional reductions indicated alongside. Solid vertical line = hazard ratio of 1.0 (ie, no effect of treatment), and dotted vertical line = observed overall effect. DVT = deep venous thrombosis; PE = pulmonary embolism; VTE = venous thromboembolism.

  • Image Result
    Proportional effects of unfractionated heparin (UFH) and low-molecular weight heparin (LMWH) on heparin-associated thrombocytopenia in patients who received either treatment or prophylaxis. Black squa

    Proportional effects of unfractionated heparin (UFH) and low-molecular weight heparin (LMWH) on heparin-associated thrombocytopenia in patients who received either treatment or prophylaxis. Black squares = point estimates (with area proportional to number of events) and horizontal lines = 95% confidence interval (CI) for observed effects in different subgroups. Diamonds = point estimate and 95% CI for overall effects, with proportional reductions indicated alongside. Solid vertical line = hazard ratio of 1.0 (ie, no effect of treatment), and dotted vertical line = observed overall effect. DVT = deep venous thrombosis; VTE = venous thromboembolism; PE = pulmonary embolism; surg = surgical; med = medical; gyn = gynecological.

 Funding: None.

 Conflict of Interest: Russell Hull has received research support from Sanofi-Aventis and Leo-pharma. He has been on advisory boards for Sanofi-Aventis, Boehringer Ingelheim, Bayer, and Pfizer. None of the authors have any conflict of interest with the content of this article.

 Authorship: All authors had access to the data and a role in writing the manuscript.

PII: S0002-9343(09)00437-9

doi: 10.1016/j.amjmed.2009.03.026

The American Journal of Medicine
Volume 122, Issue 10 , Pages 919-930 , October 2009

Article Tools

* Image Usage & Resolution